9 17

Cited 0 times in

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data

Authors
 Francesco Giovinazzo  ;  Fiammetta Soggiu  ;  Jin-Young Jang  ;  Eva Versteijne  ;  Geertjan van Tienhoven  ;  Casper H van Eijck  ;  Youngmin Han  ;  Seong Ho Choi  ;  Chang Moo Kang  ;  Mark Zalupski  ;  Hasham Ahmad  ;  Sarah Yentz  ;  Scott Helton  ;  J Bart Rose  ;  Chie Takishita  ;  Yuichi Nagakawa  ;  Mohammad Abu Hilal 
Citation
 FRONTIERS IN ONCOLOGY, Vol.10 : 1112, 2020-08 
Journal Title
 FRONTIERS IN ONCOLOGY 
Issue Date
2020-08
Keywords
Borderline resectable pancreaic adenocarcinoma ; Pancreatic ductal adenocancinoma ; gemcitabine ; gemcitabine-based neoadjuvant ; neoadjuvant treatment of pancreatic cancer
Abstract
Background: Non-randomized studies have investigated multi-agent gemcitabine-based neo-adjuvant therapies (GEM-NAT) in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC). Treatment sequencing and specific elements of neoadjuvant treatment are still under investigation. The present meta-analysis aims to assess the effectiveness of GEM-NAT on overall survival (OS) in BR-PDAC. Patients and Methods: A meta-analysis of individual participant data (IPD) on GEM-NAT for BR-PDAC were performed. The primary outcome was OS after treatment with GEM-based chemotherapy. In the Individual Patient Data analysis data were reappraised and confirmed as BR-PDAC on provided radiological data. Results: Six studies investigating GEM-NAT were included in the IPD metanalysis. The IPD metanalysis was conducted on 271 patients who received GEM-NAT. Pooled median patient-level OS was 22.2 months (95%CI 19.1-25.2). R0 rates ranged between 81 and 95% (I 2 = 0%, p = 0.64), respectively. Median OS was 27.8 months (95%CI 23.9-31.6) in the patients who received NAT-GEM followed by resection compared to 15.4 months (95%CI 12.3-18.4) for NAT-GEM without resection and 13.0 months (95%CI 7.4-18.5) in the group of patients who received upfront surgery (p < 0.0001). R0 rates ranged between 81 and 95% (I 2 = 0%, p = 0.64), respectively. Overall survival in the R0 group was 29.3 months (95% CI 24.3-34.2) vs. 16.2 months (95% CI 7·9-24.5) in the R1 group (p = 0·001). Conclusions: The present study is the first meta-analysis combining IPD from a number of international centers with BR-PDAC in a cohort that underwent multi-agent gemcitabine neoadjuvant therapy (GEM-NAT) before surgery. GEM-NAT followed by surgical resection improve survival and R0 resection in BR-PDAC. Also, GEM-NAT may result in a good palliative option in non-resected patients because of progressive disease after neoadjuvant treatment. Results from randomized controlled trials (RCTs) are awaited to validate these findings.
Files in This Item:
T202004010.pdf Download
DOI
10.3389/fonc.2020.01112
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Chang Moo(강창무) ORCID logo https://orcid.org/0000-0002-5382-4658
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180091
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links